Literature DB >> 24578483

Endovascular treatment for M2 occlusions in the era of stentrievers: a descriptive multicenter experience.

Alan Flores1, Alejandro Tomasello2, Pere Cardona3, M Angeles de Miquel3, Meritxell Gomis4, Pablo Garcia Bermejo4, Victor Obach5, Xabi Urra5, Joan Martí-Fàbregas6, David Cánovas7, Jaume Roquer8, Sònia Abilleira9, Marc Ribó1.   

Abstract

BACKGROUND: Patients with M2 middle cerebral artery (MCA) occlusions are not always considered for endovascular treatment.
OBJECTIVE: To study outcomes in patients with M2 occlusion treated with endovascular procedures in the era of stentrievers.
METHODS: We studied patients prospectively included in the SONIIA registry (years 2011-2012)-a mandatory, externally audited registry that monitors the quality of reperfusion therapies in Catalonia in routine practice. Good recanalization was defined as postprocedure Thrombolysis in Cerebral Infarction (TICI) score 2b-3; dramatic recovery as drop in National Institutes of Health Stroke Scale (NIHSS) score >10 points or NIHSS score <2 at 24-36 h; and good outcome as modified Rankin score (mRS) 0-2 at 3months. A 24 h CT scan determined symptomatic intracranial hemorrhage (SICH) and infarct volume.
RESULTS: Of 571 patients who received endovascular treatment, 65 (11.4%) presented an M2 occlusion on initial angiogram, preprocedure NIHSS 16 (IQR 6). Mean time from symptom onset to groin puncture was 289 ± 195 min. According to interventionalist preferences 86.2% (n=56) were treated with stentrievers (n=7 in combination with intra-arterial tissue plasminogen activator (tPA), 4.6% (n=3) received intra-arterial tPA only, and 9.2% (n=6) diagnostic angiography only. Good recanalization (78.5%) was associated with dramatic improvement (48% vs 14.8%; p=0.02), smaller infarct volumes (8 vs 82 cc; p=0.01) and better outcome (mRS 0-2: 66.3% vs 30%; p=0.03). SICH (9%) was not associated with treatment modality or device used. After adjusting for age and preprocedure NIHSS, good recanalization emerged as an independent predictor of dramatic improvement (OR=5.9 (95% CI 1.2 to 29.2), p=0.03). Independent predictors of good outcome at 3 months were age ( OR=1.067 (95% CI 1.005 to 1132), p=0.03) and baseline NIHSS ( OR=1.162 (95% CI 1.041 to 1.297), p<0.01).
CONCLUSIONS: Endovascular treatment of M2 MCA occlusion with stentrievers seems safe. Induced recanalization may double the chances of achieving a favorable outcome, especially for patients with moderate or severe deficit. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Angiography; Stroke; Thrombectomy

Mesh:

Year:  2014        PMID: 24578483     DOI: 10.1136/neurintsurg-2014-011100

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  16 in total

1.  Improving mTICI2b reperfusion to mTICI2c/3 reperfusions: A retrospective observational study assessing technical feasibility, safety and clinical efficacy.

Authors:  Johannes Kaesmacher; Christian Maegerlein; Felix Zibold; Silke Wunderlich; Claus Zimmer; Benjamin Friedrich
Journal:  Eur Radiol       Date:  2017-07-27       Impact factor: 5.315

2.  Thrombectomy for M2 occlusions and the role of the dominant branch.

Authors:  Luís Henrique de Castro Afonso; Guilherme Borghini Pazuello; Guilherme Seizem Nakiri; Lucas Moretti Monsignore; Francisco Antunes Dias; Octávio Marques Pontes-Neto; Daniel Giansante Abud
Journal:  Interv Neuroradiol       Date:  2019-05-14       Impact factor: 1.610

Review 3.  Unresolved Issues in Thrombectomy.

Authors:  Mahesh V Jayaraman; Ryan A McTaggart; Mayank Goyal
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

4.  Mechanical thrombectomy in stroke patients with acute occlusion of the M1- compared to the M2-segment: Safety, efficacy, and clinical outcome.

Authors:  Daniel Weiss; Christian Rubbert; Vivien L Ivan; John-Ih Lee; Michael Gliem; Sebastian Jander; Julian Caspers; Bernd Turowski; Marius G Kaschner
Journal:  Neuroradiol J       Date:  2022-03-04

5.  Effect of endovascular reperfusion in relation to site of arterial occlusion.

Authors:  Robin Lemmens; Scott A Hamilton; David S Liebeskind; Tom A Tomsick; Andrew M Demchuk; Raul G Nogueira; Michael P Marks; Reza Jahan; Jan Gralla; Albert J Yoo; Sharon D Yeatts; Yuko Y Palesch; Jeffrey L Saver; Vitor M Pereira; Joseph P Broderick; Gregory W Albers; Maarten G Lansberg
Journal:  Neurology       Date:  2016-01-22       Impact factor: 9.910

6.  Mechanical Thrombectomy for Isolated M2 Occlusions: A Post Hoc Analysis of the STAR, SWIFT, and SWIFT PRIME Studies.

Authors:  J M Coutinho; D S Liebeskind; L-A Slater; R G Nogueira; B W Baxter; E I Levy; A H Siddiqui; M Goyal; O O Zaidat; A Davalos; A Bonafé; R Jahan; J Gralla; J L Saver; V M Pereira
Journal:  AJNR Am J Neuroradiol       Date:  2015-11-12       Impact factor: 3.825

7.  M2 occlusions as targets for endovascular therapy: comprehensive analysis of diffusion/perfusion MRI, angiography, and clinical outcomes.

Authors:  Sunil A Sheth; Bryan Yoo; Jeffrey L Saver; Sidney Starkman; Latisha K Ali; Doojin Kim; Nestor R Gonzalez; Reza Jahan; Satoshi Tateshima; Gary Duckwiler; Fernando Vinuela; David S Liebeskind
Journal:  J Neurointerv Surg       Date:  2014-05-12       Impact factor: 5.836

8.  Internal Carotid Artery and the Proximal M1 Segment Are Optimal Targets for Mechanical Thrombectomy.

Authors:  Niko Sillanpää; Sara Protto; Jukka T Saarinen; Juha-Pekka Pienimäki; Janne Seppänen; Heikki Numminen; Harri Rusanen
Journal:  Interv Neurol       Date:  2017-05-19

9.  Mechanical Thrombectomy for M2 Occlusions: A Single-Centre Experience.

Authors:  Pervinder Bhogal; Philipp Bücke; Marta Aguilar Pérez; Oliver Ganslandt; Hansjörg Bäzner; Hans Henkes
Journal:  Interv Neurol       Date:  2017-02-16

10.  Manual Aspiration Thrombectomy Using Penumbra Catheter in Patients with Acute M2 Occlusion : A Single-Center Analysis.

Authors:  Jung Soo Park; Hyo Sung Kwak
Journal:  J Korean Neurosurg Soc       Date:  2016-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.